Amalgamated Bank Sells 7,287 Shares of DaVita Inc. (NYSE:DVA)

Amalgamated Bank lessened its holdings in shares of DaVita Inc. (NYSE:DVA) by 42.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,032 shares of the company’s stock after selling 7,287 shares during the quarter. Amalgamated Bank’s holdings in DaVita were worth $1,645,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in DVA. Harvard Management Co. Inc. bought a new position in DaVita in the 2nd quarter worth $55,115,000. Lazard Asset Management LLC lifted its holdings in DaVita by 147.3% in the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after buying an additional 153,008 shares during the period. Andra AP fonden boosted its position in DaVita by 9.0% during the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company’s stock valued at $26,647,000 after acquiring an additional 15,800 shares in the last quarter. abrdn plc grew its holdings in shares of DaVita by 1.2% during the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock worth $30,719,000 after acquiring an additional 2,180 shares during the period. Finally, Jupiter Asset Management Ltd. raised its position in shares of DaVita by 146.7% in the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after acquiring an additional 111,311 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the topic of several recent research reports. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial raised their target price on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Barclays increased their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, TD Cowen raised their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and an average price target of $161.80.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 165,625 shares of company stock valued at $26,238,297. Corporate insiders own 2.00% of the company’s stock.

DaVita Stock Up 2.3 %

DaVita stock opened at $158.03 on Wednesday. The firm has a market cap of $12.96 billion, a price-to-earnings ratio of 17.05, a PEG ratio of 0.84 and a beta of 0.89. The stock has a fifty day simple moving average of $157.34 and a two-hundred day simple moving average of $147.23. DaVita Inc. has a 12 month low of $84.64 and a 12 month high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.85 EPS. Equities analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.